Latest Breaking News On - Novartis president - Page 1 : comparemela.com

Novartis drug candidate atrasentan met the main goal of a pivotal study in the chronic kidney disease IgA nepropathy. It’s one of two drugs added via the multi-billion dollar acquisition of Chinook Therapeutics; together with a homegrown therapeutic candidate, they give Novartis three different approaches to treat the rare disorder.

Shreeram aradhyeChinook therapeuticsTherapeutic tarpeyoTravere therapeuticsNovartis presidentChief medical officerWeight lossMedical devicesHealthcare innovationMedcity newsMedcity newsSan franciscoLife sciencesRock healthStartup adviceStartup funding